LumiThera Announces Top Line Data in the European Multi-Center, LIGHTSITE II Clinical Study to Treat Dry Age-Related Macular Degeneration

SEATTLE, April 7, 2021 /PRNewswire/ — LumiThera Inc., a commercial stage medical device company delivering photobiomodulation (PBM) treatment for ocular disorders and disease, today announced positive findings in its LIGHTSITE II, multi-center clinical trial in dry Age-Related Macular Degeneration (AMD) patients. The prospective, double-masked, randomized, multi-center, European Union post-marketing clinical trial, titled LIGHTSITE II, was… Continue reading →

LumiThera Announces Positive Interim Data in Visual and ERG Clinical Outcomes in the ELECTROLIGHT Pilot Study in Dry AMD patients

SEATTLE, Feb. 16, 2021 /PRNewswire/ — LumiThera Inc., a commercial stage medical device company offering a photobiomodulation (PBM) treatment for ocular damage and disease, today announced the interim data from the ELECTROLIGHT pilot study in dry AMD patients. A total of 23 eyes from 15 subjects with intermediate Dry AMD were enrolled into the prospective… Continue reading →

LumiThera listed as 1 of 10 Startups to Watch

LumiThera is a Poulsbo-based medical device company that harnesses the healing power of light. Founded by Clark E. Tedford, Ph.D. and a team of two eye doctors and two engineers, LumiThera was conceived with the goal of developing a noninvasive treatment for degenerative eye disease. Tedford has more than 30 years of experience in the… Continue reading →

LumiThera Completes Patient Enrollment in the U.S. Multi-Center, LIGHTSITE III Clinical Study to Treat Dry Age-Related Macular Degeneration

SEATTLE, Feb 10, 2021 /PRNewswire/ — LumiThera, Inc., a commercial stage medical device company delivering photobiomodulation (PBM) treatment for ocular disorders and diseases, today announced it has completed enrollment in its multi-center United States clinical study in non-neovascular (dry) Age-Related Macular Degeneration (AMD) patients. The randomized, multi-center study, LIGHTSITE III, enrolled the last patient at the Byers Eye Institute… Continue reading →

LumiThera Announces Ryan Montecucco as General Counsel

SEATTLE, Nov. 12, 2020 /PRNewswire/ — LumiThera Inc., a commercial stage medical device company delivering photobiomodulation (PBM) treatment for ocular disorders and diseases, today announced it has added Ryan Montecucco as General Counsel and Secretary. “We are very pleased to have Ryan join our team,” stated Clark Tedford, Ph.D., President and CEO. “Ryan has been… Continue reading →

LumiThera and Diopsys Announce Collaboration and Enrollment of First Subject in the ELECTROLIGHT Study in Dry AMD patients

SEATTLE, Sept. 10, 2020 /PRNewswire/ — LumiThera Inc., a commercial stage medical device company creating a photobiomodulation (PBM) treatment for ocular disorders and disease, today announced it is collaborating with Diopsys, a leading provider of modern visual electrophysiology solutions. Diopsys’ technology helps eye care professionals accurately and objectively measure retinal and visual pathway function. The… Continue reading →

A DOUBLE-MASKED, RANDOMIZED, SHAM-CONTROLLED, SINGLE-CENTER STUDY WITH PHOTOBIOMODULATION FOR THE TREATMENT OF DRY AGE-RELATED MACULAR DEGENERATION

Purpose: The LIGHTSITE I study investigated the efficacy and safety of photobiomodulation (PBM) treatment in subjects with dry age-related macular degeneration. Methods: Thirty subjects (46 eyes) were treated with the Valeda Light Delivery System, wherein subjects underwent two series of treatments (3× per week for 3–4 weeks) over 1 year. Outcome measures included best-corrected visual… Continue reading →

Posted on September 5th, 2020 in Articles

LumiThera Receives Notice of Award for $1.5 Million National Eye Institute Grant to Support U.S. Multi-Center Clinical Trial for Treating Diabetic Retinopathy and Macular Edema

SEATTLE, Sept. 3, 2020 /PRNewswire/ — LumiThera Inc., a commercial stage medical device company creating a photobiomodulation (PBM) treatment for ocular disorders and disease, today announced it is a recipient of a small business innovative research (SBIR) phase II grant from the National Institute of Health (NIH) and the division of the National Eye Institute… Continue reading →

LumiThera Closes Series C Round of Financing

SEATTLE, July 8, 2020 /PRNewswire/ — LumiThera Inc., a commercial stage private medical device company, creating a multi-wavelength photobiomodulation (PBM) treatment for ocular disorders and diseases, today announced it has completed its Series C financing. The company raised approximately $14M to support further commercialization of its Valeda Light Delivery System for the treatment for dry… Continue reading →

Photobiomodulation as a Treatment in Dry AMD

Doctors and patients have found this new mode of therapy beneficial. By Hakan Kaymak, MD; and Hartmut Schwahn, PhD The development of innovative treatments for debilitating diseases such as age-related macular degeneration (AMD) is crucial to advance patient care and to reduce burdens on patients, caregivers, and physicians. The dry, or nonexudative, form of AMD… Continue reading →